Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
NEW YORK (Reuters Health) – Treatment with the third generation bisphosphonate zoledronic acid (Zometa) may improve survival in lung cancer patients with bone metastases, Greek researchers report. Between…
NEW YORK (Reuters Health) – While minimally invasive radical prostatectomy (MIRP) offers certain advantages over open retropubic radical prostatectomy (RRP), such as a shorter hospital stay, it also…
NEW YORK (Reuters Health) – Tamoxifen therapy has been linked to an increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) and now new research suggests…
NEW YORK (Reuters Health) – In patients receiving first-line treatment for metastatic colon cancer, planned complete discontinuation of chemotherapy had a negative impact on duration of disease control…
NEW YORK (Reuters Health) – In a phase III trial in women with HER2/hormone receptor-copositive metastatic breast cancer, the combination of trastuzumab plus anastrozole improved outcomes compared to…
NEW YORK (Reuters Health) – For patients with primary cutaneous melanoma, targeted high-resolution ultrasound should not be used as a substitute for excisional sentinal lymph node biopsy, new…
NEW YORK (Reuters Health) – In detecting prostate cancer, no single prostate specific antigen (PSA) cut-off value achieves the likelihood ratios usually required of a screening test, according…
NEW YORK (Reuters Health) – New research indicates that over half of men who choose watchful waiting as the initial strategy for prostate cancer require no treatment on…
NEW YORK (Reuters Health) – In premenopausal women with breast cancer, adjuvant tamoxifen treatment significantly reduces the risk of contralateral breast cancer, according to results of a Swedish…
NEW YORK (Reuters Health) – Treatment with estrogen plus progestin does not seem to increase the risk of lung cancer per se, but it may increase the odds…
